Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal
Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish drugmaker's second deal this week, as it looks to strengthen the pipeline of its weight-loss treatments.
As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.
Obesity drug giant Novo Nordisk said Thursday that the rampant growth of the U.S.'s compounded drug industry was hurting ...
Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.
Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...
We recently published a list of 10 Stocks Wall Street Is Calling Bullish Amid Market Turmoil. In this article, we are going ...
The issuer is solely responsible for the content of this announcement.
Meanwhile, other companies large and small are racing to develop their own obesity products, so Novo Nordisk has to step lively to continue succeeding in the segment. Ever feel like you missed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback